Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm, Residual × Calcium × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Osteoporosis 7 Breast Neoplasms 7 Colorectal Neoplasms 4 Bone Diseases, Metabolic 4 Vitamin D Deficiency 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pain 2 Lymphoma 2 Leukemia 2 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Polycystic Ovary Syndrome 1 Pancreatic Neoplasms 1 Paclitaxel-induced Neuropathy 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Kidney Neoplasms 1 Head and Neck Neoplasms 1 Dwarfism, Pituitary 1 Disease Progression 1 Colonic Polyps 1 Carcinoma, Transitional Cell 1 Arthralgia 1 Adenomatous Polyps 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 21 blinatumomab 16 Cytarabine 14 fludarabine 13 Azacitidine 11 venetoclax 9 fludarabine phosphate 9 Blood Specimen Collection 8 Rituximab 7 Methotrexate 7 Dexamethasone 7 Daunorubicin 7 Lenalidomide 6 Vincristine 5 Mercaptopurine 5 daratumumab 4 Whole-Body Irradiation 4 Melphalan 4 Idarubicin 4 Etoposide 4 obinutuzumab 3 Liquid Biopsy 3 Imatinib Mesylate 3 Granulocyte Colony-Stimulating Factor 3 Doxorubicin 3 Cladribine 3 Chemotherapy, Adjuvant 3 Busulfan 3 Asparaginase 3 trastuzumab deruxtecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00172068 2009-12-23

MRD-1

Novartis

Phase 2 Terminated

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon ⚡